Phenominer Database Results (11 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Record ID Study ID
SHRSP/A3N both kidneys wet weight to body weight ratio controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney mass male 126 days-182 days 0 8.8 g/kg 0.4 post excision weight measurement kidney 0.0 0 107536 3090
SHRSP/A3N kidney total tubule cast count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 4.0 /section 3.0 ex vivo light microscopy with histochemistry 0.0 0 107556 3090
SHRSP/A3N kidney glomerular lesion count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney glomerulus integrity trait male 126 days-182 days 0 1.4 /section 1.0 ex vivo light microscopy with histochemistry renal glomerulus 0.0 0 107540 3090
SHRSP/A3N body weight controlled sodium chloride content drinking water (1 %) (for 42 days) and controlled fat content diet (24.5 %) (for 42 days) and eprosartan (60 mg/kg/d) (for 42 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. body mass male 126 days-147 days 0 298.0 g 2.0 body weighing method 0.0 0 107528 3090
SHRSP/A3N renal fibrosis foci count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 7.1 /section 0.3 ex vivo light microscopy with histochemistry 0.0 0 107560 3090
SHRSP/A3N kidney weight controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney mass male 126 days-182 days 0 2.77 g 0.2 post excision weight measurement kidney 0.0 0 107532 3090
SHRSP/A3N systolic blood pressure controlled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and eprosartan (60 mg/kg/d) (for 84 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. arterial blood pressure trait male 168 days-189 days 6 serial mean 250.0 mmHg 9.0 22.05 tail cuff plethysmography tail 0.0 0 average 3 week intervals for 12 weeks 107500 3090
SHRSP/A3N ratio of deaths related to chronic hypertension to total study population during a period of time controlled sodium chloride content drinking water (1 %) (for 84 days) and controlled fat content diet (24.5 %) (for 84 days) and eprosartan (60 mg/kg/d) (for 84 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total life span male 168 days-189 days 25 0.0 % unspecified method 0.0 0 ratio of deaths related to chronic hypertension to total study population during a period of time (CMO:0003800) 107519 3090
SHRSP/A3N urine total protein excretion rate controlled sodium chloride content drinking water (1 %) (between 35 and 49 days) and controlled fat content diet (24.5 %) (between 35 and 49 days) and eprosartan (60 mg/kg/d) (between 35 and 49 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. total urine protein amount male 119 days-154 days 0 22.0 mg/d 2.0 urine protein analysis 86400.0 0 107521 3090
SHRSP/A3N kidney tubule regeneration foci count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 0.0 /section 0.0 ex vivo light microscopy with histochemistry 0.0 0 107548 3090
SHRSP/A3N interstitial nephritis foci count controlled sodium chloride content drinking water (1 %) (between 42 and 77 days) and controlled fat content diet (24.5 %) (between 42 and 77 days) and eprosartan (60 mg/kg/d) (between 42 and 77 days) Abrahamsen CT, etal., J Pharmacol Exp Ther. 2002 Apr;301(1):21-8. doi: 10.1124/jpet.301.1.21. kidney integrity trait male 126 days-182 days 0 1.0 /section 0.4 ex vivo light microscopy with histochemistry 0.0 0 107552 3090